| Item number | Description | Mass (g) | Volume (mL) | Size — height × width × depth (mm) | Connector | Maximum programmed / delivered energy (J) |
|---|---|---|---|---|---|---|
| DVME3D1 | Mirro MRI™ single-chamber | 77 | 33 | 66 × 51 × 13 | IS-1 / DF-1 | 35 / 36 |
| DVME3D4 | Mirro MRI™ single-chamber | 77 | 33 | 64 × 51 × 13 | IS-1/ DF-4 | 35 / 36 |
| DDME3D1 | Mirro MRI™ dual-chamber | 77 | 33 | 66 × 51 × 13 | IS-1 / DF-1 | 35 / 36 |
| DDME3D4 | Mirro MRI™ dual-chamber | 78 | 34 | 68 × 51 × 13 | IS-1 / DF-4 | 35 / 36 |
Implantable cardioverter defibrillators
Mirro MRI™ SureScan™ ICD
<p>The Mirro MRI™ SureScan™ ICD is approved for use in the MR environment, when MR conditions for use are met.</p>
Features
Shock reduction
Lead integrity alert
- Lead integrity alert (LIA) is designed to provide advance warning for lead fracture and reduce the patient’s risk of inappropriate shocks.
- 72% of patients monitored by LIA either did not receive an inappropriate shock or had at least a three-day warning before being shocked, compared to 50% of patients monitored by lead impedance only.1
- In addition, LIA detected more lead issues than lead impedance monitoring alone with St. Jude Medical Riata™* and Durata™* leads, and Boston Scientific Endotak™* leads.2
No inappropriate shock or ≥ 3-day warning
Lead integrity
alert
72%
Lead impedance
monitoring
50%
Longer nominal ventricular fibrillation (VF) number of intervals to detect (NID)
- ADVANCE III found that the use of a longer NID (VF NID = 30/40) yielded a 39% reduction in appropriate but unnecessary therapies compared to a shorter detection interval (VF NID = 18/24).3
- Antitachycardia pacing (ATP) during charging, in addition to VF NID = 30/40, resulted in another 52% reduction in unnecessary shocks.3
- Mirro MRI™ ICD combines our exclusive ATP before and during charging with a long detection interval to minimize shocks.4
39%
Reduction in appropriate but unneccesary therapies when VF NID = 30/40
Mirro™ MRI nominal VF NID = 30/40
Improved longevity
20% increased longevity compared to Protecta™ ICD with a new battery, new capacitors, and enhanced circuit efficiencies.4–7
| Protecta™ DR ICD | 8 years
|
| Mirro MRI™ DR ICD | 9.7 years
|
| Protecta™ VR ICD | 9 years
|
| Mirro MRI™ VR ICD | 11 years
|
Ordering information
Similar products
-
Aurora EV-ICD™ systemThe Aurora EV-ICD™ system is used to treat sudden cardiac arrest and abnormal heart rhythms with defibrillation and antitachycardia pacing (ATP).
-
Cobalt XT™ MRI SureScan™ ICDCobalt™ XT ICDs are used to treat sudden cardiac arrest and abnormal heart rhythms.
-
Cobalt™ MRI SureScan™ ICDCobalt™ ICDs are used to treat sudden cardiac arrest and abnormal heart rhythms.
-
Crome MRI™ SureScan™ ICDCrome™ ICDs are used to treat sudden cardiac arrest and abnormal heart rhythms.
-
Primo MRI™ SureScan™ ICDPrimo MRI™ SureScan™ ICD is approved for use in the MR environment when MR conditions for use are met.
-
Visia AF™ MRI SureScan™ ICDThe Visia AF™ MRI SureScan™ implantable cardioverter defibrillator (ICD) is issued for tachyarrhythmia management.
TM* Third-party brands are trademarks of their respective owners.
- Swerdlow CD, Gunderson B, Ousdigian K, Sachanandani H, Ellenbogen K. HRS Conference 2010.
- Ellenbogen KA, Gunderson BD, Stromberg KD, Swerdlow CD. Performance of lead integrity alert to assist in the clinical diagnosis of implantable cardioverter defibrillator lead failures: analysis of different implantable cardioverter defibrillator leads. Circ Arrhythm Electrophysiol. 2013;6(6):1169–1177.
- Arenal A, Proclemer A, Kloppe A, et al. Different impact of long-detection interval and anti-tachycardia pacing in reducing unnecessary shocks: data from the ADVANCE III trial. Europace. 2016;18(11):1719–1725.
- Mirro MRI™ DR SureScan DDME3D4 device manual. manuals.medtronic.com.
- Protecta™ XT DR D354DRM clinician manual. manuals.medtronic.com.
- Protecta™ XT VR D354VRM clinician manual. manuals.medtronic.com.
- Mirro MRI™ VR SureScan DVME3D4 device manual. manuals.medtronic.com.